Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
1,200
NCT06879327
Infant Malaria Vaccine Schedule Optimization
Phase: Phase 2
Role: Collaborator
Start: May 30, 2025
Completion: Mar 22, 2028